Cynapsedx
WebGemelli Biotech's main competitors include Vivid Genomics, ALCEDIAG, Quadrant Biosciences and CynapseDx. Compare Gemelli Biotech to its competitors by revenue, employee growth and other metrics at Craft. Advanced Product Craft Intelligence Portal Craft API Supplier Intelligence Platform Company Search (Free) Solutions Craft for … WebCynapseDx's key executives include Damian Bond and 2 others. Damian Bond Chief Executive Peter Foster Chairman Christopher Stanley Chief Technology Officer Source: cynapsedx.com Report incorrect company information Key Executive Tracking Receive notifications of key executive changes Get started Executives of similar companies Vivid …
Cynapsedx
Did you know?
WebSummary Overview Number of Founded Organizations 1 CB Rank (Person) 672,540 Gender Male Christopher Stanley is the co-founder of CynapseDx. Jobs Number of Current Jobs 1 Christopher Stanley is the Co-Founder & CTO at CynapseDx. CynapseDx Co-Founder & CTO Recent News and Activity There is no recent news or activity for this profile. http://cynapsedx.com/contact-us
WebCynapseDx Connect to CRM Summary Financials People Technology Signals & News Similar Companies Highlights Employee Profiles 2 About CynapseDx has 2 current employee profiles, including Co-Founder & CTO Christopher Stanley. Contacts We're working on getting contact data for CynapseDx Find more contact data in Search! Get … http://cynapsedx.com/testing-neurodegeneration
WebCynapseDx Limited Liverpool Science Park 131 Mount Pleasant Liverpool L3 5TF; 0151 705 3400; [email protected] WebCynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as …
WebCynapseDx has been developing products to isolate proteins or cells from whole blood since 2012. At the heart of our techniques is a concentration step, which enriches the …
WebCynapseDx is currently conducting a trial to demonstrate that our assays can save money and resources for any health service by cost effectively identifying patients mis-diagnosed with Parkinson’s disease. This will secure the funding to complete the development of all 3 assays for ß-amyloid, α-synuclein and phospho-tau. ... orbax university of guelphWebwww.cynapsedx.com/about-us Formerly Known As Cell Cap Technologies Ownership Status Acquired/Merged (Operating Subsidiary) Financing Status Formerly VC-backed … ipmitool callin link authWebcynapsedx.com Claim your profile to get in front of buyers, investors, and analysts. Submit Your Analyst Briefing Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Learn more. Overview & Products Financials People Alternatives & Competitors Customers CynapseDx has not claimed their Profile. orbax oral solutionorbax oral suspension for dogshttp://mta.cynapsedx.com/partnering ipmitool bmc resetWebCynapseDx has incorporated three technical enhancements to allow us to measure the oligomeric and aggregated forms of these biomarker proteins in blood. Immunoconcentration. We use antibody-coated magnetic … orbax used forWebCynapseDx develops products to isolate proteins or cells from whole blood. Its primary focus is neurodegenerative diseases, such as Parkinson’s or Alzheimer’s Disease. ipmitool bootdev options